P2‐039: PROGRESS OF THE PHASE I CLINICAL TRIAL TO EVALUATE LONGEVERON ALLOGENEIC MESENCHYMAL STEM CELLS (LMSCS) AS A POTENTIAL THERAPEUTIC FOR ALZHEIMER'S DISEASE. (1st July 2019)